Short‐term evaluation of autologous transplantation of bone marrow–derived mesenchymal stem cells in patients with cirrhosis: Egyptian study

Amin, Maha M; Sabry, Dina; Rashed, Laila A.; Aref, Wael; El‐ghobary, Mohamed; Salah, Mona; Fouad, Hany Ahmed; Youssef, Youssef Abdel-Aziz

doi:10.1111/ctr.12179

Cited by 81 publications

(70 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the field of liver cirrhosis, as shown in Table 1, many autologous [70][71][72][73][74][75][76][77][78][79][80][81][82][83] and four allogeneic [59][60][61][62] MSC therapies involving a variety of tissue origins and administration routes have been reported. Although details regarding the mechanisms of therapeutic effects in humans remain unclear, most studies have reported favorable effects with improvement in MELD scores, Child-Pugh scores, and some serum markers such as albumin and bilirubin.…”

Section: Mscsmentioning

confidence: 99%

Status of and candidates for cell therapy in liver cirrhosis: overcoming the “point of no return” in advanced liver cirrhosis

Terai

Tsuchiya

2016

J Gastroenterol

View full text Add to dashboard Cite

The treatment of liver cirrhosis is currently being standardized and developed specifically to reduce activation of hepatic stellate cells (HSCs), inhibit fibrosis, increase degradation of matrix components, and reduce activated myofibroblasts. Cell therapy can be applied in the treatment of liver cirrhosis; however, the characteristic features of this therapy differ from those of other treatments because of the involvement of a living body origin and production of multiple cytokines, chemokines, matrix metalloproteinases (MMPs), and growth factors. Thus, cell therapies can potentially have multiple effects on the damaged liver, including alleviating liver cirrhosis and stimulating liver regeneration with affecting the host cells. Cell therapies initially involved autologous bone marrow cell infusion, and have recently developed to include the use of specific cells such as mesenchymal stem cells and macrophages. The associated molecular mechanisms, routes of administration, possibility of allogeneic cell therapy, and host conditions appropriate for cell therapies are now being extensively analyzed. In this review, we summarize the status and future prospects of cell therapy for liver cirrhosis.

show abstract

Section: Mscsmentioning

confidence: 99%

Status of and candidates for cell therapy in liver cirrhosis: overcoming the “point of no return” in advanced liver cirrhosis

Terai

Tsuchiya

2016

J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Recently, a pilot study was conducted to evaluate the safety and efficacy of autologous BM-MSCs in 20 liver cirrhosis patients. These patients received an intrasplenic injection of 10 × 10 6 BM-MSCs and were monitored for 10 months [56]. This study further validated that autologous BM-MSC transfusion significantly improves liver function, whereby the serum bilirubin, AST and ALT levels, prothrombin time and International Normalized Ratio (INR) decreased, while serum albumin levels increased.…”

Section: Allogeneic Stem Cells In Liver Cirrhosis Therapymentioning

confidence: 59%

Adult Stem Cell Therapy in Liver Cirrhosis Management: Current Practices and Future Perspectives

Subbanna¹,

Radha²,

Choy³

et al. 2017

Int J Stem Cell Res Ther

View full text Add to dashboard Cite

“…Similarly, recent study observed shortterm efficacy of autologous BM-MSCs transplantation in liver failure patients caused by viral hepatitis B. The liver function and MELD score were significantly improved in the transplantation group as compared to the control group for 2-3 weeks post-transplantation and these effects could sustain 36 weeks [87]. Currently, autologous BM-MSCs transplantation showed safety, feasibility and efficacy in improving liver function of Egyptian patients with cirrhosis.…”

Section: Clinical Trials In Humanmentioning

confidence: 78%

Mesenchymal Stem Cells: Current Clinical Applications and Therapeutic Potential in Liver Diseases

Prasajak¹

2014

J Bone Marrow Res

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are one of valuable candidates for cell-based therapy which trend to be safe, feasible and promising in the treatment of several diseases. Since, MSCs possess unique biological characteristics which make them variable applying in clinic. These include self-renewal capacity, multi-lineages differentiation potential, homing and migration ability, immunomodulatory properties and paracrine secretion activity. These beneficial advantages lead to increase possibility of using MSCs in several implications such as regenerative medicine, tissue engineering, cells-based therapy and other clinical applications. At present, many clinical trials related to MSCs have been conducted in various diseases including bone defect, myocardial infarction, spinal injury, critical limb ischemia, diabetes and multiple sclerosis based on registered data at http://clinicaltrials.gov. The most of these clinical trials are being under investigation and are in phase I and II. There are several diseases of the liver that cause liver dysfunction due to hepatocytes injury and loss including viral hepatitis, fatty liver disease, drug or toxin induced liver injury, hepatocellular carcinoma, autoimmuneassociated hepatic disorders and cirrhosis. In this review, we focus on mesenchymal stem cell (MSCs) toward liver disease treatment by MSCs therapy. In this regard, we summarized characteristics of mesenchymal stem cell (MSCs) including sources, general characteristics, differentiation potential, niches, and biological effects of the cells. We also emphasized on current methods for hepatocyte differentiation and current board clinical applications. The current studies of MSCs both in preclinical and clinical trials related to liver diseases are also discussed in context of possible application in therapeutic purposes in this review. Understanding the basic knowledge of MSCs and their therapeutic capability in preclinical and clinical studies will accelerate therapeutic value of MSCs transplantations for disease treatments, drug screening, stem cell banking and regenerative medicine.

show abstract

Short‐term evaluation of autologous transplantation of bone marrow–derived mesenchymal stem cells in patients with cirrhosis: Egyptian study

Cited by 81 publications

References 20 publications

Status of and candidates for cell therapy in liver cirrhosis: overcoming the “point of no return” in advanced liver cirrhosis

Status of and candidates for cell therapy in liver cirrhosis: overcoming the “point of no return” in advanced liver cirrhosis

Adult Stem Cell Therapy in Liver Cirrhosis Management: Current Practices and Future Perspectives

Mesenchymal Stem Cells: Current Clinical Applications and Therapeutic Potential in Liver Diseases

Contact Info

Product

Resources

About